Project Grant R61AG094604
- The National Institute on Aging awarded The University of Texas Health Science Center at San Antonio $1.112 million on September 20, 2025, under the Aging Research program (CFDA 93.866) to deliver advanced training in cross-national research on cognitive aging and Alzheimer's disease and related dementias using harmonized datasets from the Health and Retirement Study and the Harmonized Cognitive Assessment Protocol. The award funds five annual intensive courses for advanced-doctoral,...
- The National Institute on Aging awarded the University of Texas at Austin $10.686 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to investigate remotely-supervised neuromodulation paired with language treatment for the logopenic variant of primary progressive aphasia, a progressive language disorder caused by underlying Alzheimer's disease pathology. The award supports research to enhance proven language treatment for LVPPA by combining it with tailored, home-based...
- The National Institute on Aging awarded New York University $6.203 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to examine peripheral immune markers and vascular dysfunction as contributors to cognitive decline and Alzheimer's disease. The research integrates circulating biomarkers—platelet aggregation, neutrophil activity, and proteomic data—with advanced imaging to assess associations between vascular and immune dysfunction and cerebrovascular burden, amyloid...
- The National Institute on Aging awarded the University of California, Los Angeles $123,876 on March 15, 2026, under the Aging Research program (CFDA 93.866) to investigate occupational determinants of cognitive and brain health among middle-aged and older Latinos in the U.S. The research examines how physical and mental occupational stressors, as well as occupational complexity, affect cognitive function and brain aging in U.S. Latinos, with particular focus on immigrant Latinas in rural and...
- The National Institute on Aging awarded Texas A&M University $640,059 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate cerebellar changes in aging and cognitive decline through longitudinal neuroimaging and functional analysis. The project examines how cerebellar structure, white matter circuits, and task-based functional activation change over time in older adults, with particular focus on individuals experiencing subjective cognitive decline—self-reported...
- The National Institute on Aging awarded the University of Southern California $695,789 on January 1, 2026, under the Aging Research program (CFDA 93.866) to develop HGEA-NET, a multiscale computational model of the hippocampus that integrates cell type-specific gene expression and connectivity data to understand how progressive neurodegeneration of vulnerable neuronal populations leads to hippocampal network dysfunction and cognitive decline in Alzheimer's disease. The project builds on USC's...
- The National Institute on Aging awarded the University of Texas at Austin $650,447 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop a profile-based framework for matching transitional care services to distinct patient-caregiver groups among persons living with dementia (PLWDs). The award funds research to identify patient-caregiver profiles and co-develop provider and system implementation tools that enable tailored, evidence-based transitional care delivery across...
- The National Institute on Aging awarded the University of Texas Health Science Center at Houston $429,000 on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct a developmental research project estimating the effectiveness of hearing aid initiation in reducing incident Alzheimer's disease and related dementias among older adults. The recipient will use target trial emulation with real-world data from the Texas All-Payor Claims Database to assess hearing aid effectiveness...
- The National Institute on Aging awarded the University of California, Los Angeles $623,176 on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct research on modifiable risk factors for Alzheimer's disease and related dementias among individuals aged 90 and older. The research triangulates evidence across four data sources—the LifeAfter90 Study (1,397 participants, all aged 90), the 90+ Study (1,630 participants, all aged 90), the Health and Retirement Study (3,359...
- The National Institute on Aging awarded The University of Texas Health Science Center at San Antonio $2,147,145 on September 15, 2026, under the Aging Research program (CFDA 93.866) to conduct the Rural Microvascular Contributions to Neurocognitive Decline (RURAL-MIND) study. The study deploys portable MRI neuroimaging, AI-driven image analytics, repeated plasma biomarker profiling, and longitudinal cognitive assessments across 4,000 rural residents in high- and lower-risk counties to...
The National Institute on Aging awarded the University of Houston System $727,093 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop a community-engaged translational research network advancing Spanish-language neuropsychological assessment tools for cognitive aging and Alzheimer's disease research. The project, titled "Development of a Community Engaged Translational Research Network to Advance Spanish-Language Neuropsychological Assessment in Cognitive Aging Research: ECHAR-TR," addresses disparities in early detection and diagnosis of Alzheimer's disease and related dementias among Hispanic older adults. The network will establish infrastructure for rigorously creating and validating Spanish-language neuropsychological assessment tools through collaboration among neuropsychologists, community partners, and health providers. This Phase I (R61) award funds network establishment and identification of cognitive health needs across multiple sites. A planned Phase II (R33) will develop and pilot assessment tools in clinical research settings, refining them through psychometric analyses and cross-site feedback prior to broader dissemination. The award supports a community-to-research, lab-to-clinic model designed to generate scalable assessment tools and shared resources for accurate diagnosis and clinical decision-making in Spanish-speaking populations. Performance takes place in Houston, Texas, with a period of performance from September 1, 2026, through August 31, 2028.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $727.1k | 8/31/26 |